CD8A and neoplasm: In case of tumor cell surface membrane aberrant expression of TSA or TAA, MHC class I, and NK cells activating molecules, immunotherapeutic approaches that manipulate number and activity of antibody, CD4+, CD8+, NK cells and macrophages are of limited effect.